Page:United States Statutes at Large Volume 124.djvu/1007

 124 STAT. 981 PUBLIC LAW 111–148—MAR. 23, 2010 ‘‘(iii) a representative of the Office of the Under Secretary for Health for the Veterans Health Adminis- tration, recommended by the Secretary of Veterans Affairs; ‘‘(iv) a representative of the National Science Foundation, recommended by the Chair of the National Science Board; and ‘‘(v) a representative of the Food and Drug Administration, recommended by the Commissioner of Food and Drugs. ‘‘(B) TERMS.—Each ex-officio member shall serve a 3- year term on the Board, except that the Chairperson may adjust the terms of the initial ex-officio members in order to provide for a staggered term of appointment for all such members. ‘‘(4) RESPONSIBILITIES OF THE BOARD AND THE DIRECTOR OF NIH.— ‘‘(A) RESPONSIBILITIES OF THE BOARD.— ‘‘(i) IN GENERAL.—The Board shall advise, and pro- vide recommendations to, the Director of NIH with respect to— ‘‘(I) policies, programs, and procedures for car- rying out the duties of the Director of NIH under this section; and ‘‘(II) significant barriers to successful trans- lation of basic science into clinical application (including issues under the purview of other agen- cies and departments). ‘‘(ii) REPORT.—In the case that the Board identifies a significant barrier, as described in clause (i)(II), the Board shall submit to the Secretary a report regarding such barrier. ‘‘(B) RESPONSIBILITIES OF THE DIRECTOR OF NIH.—With respect to each recommendation provided by the Board under subparagraph (A)(i), the Director of NIH shall respond in writing to the Board, indicating whether such Director will implement such recommendation. In the case that the Director of NIH indicates a recommendation of the Board will not be implemented, such Director shall provide an explanation of the reasons for not implementing such recommendation. ‘‘(5) MEETINGS.— ‘‘(A) IN GENERAL.—The Board shall meet 4 times per calendar year, at the call of the Chairperson. ‘‘(B) QUORUM; REQUIREMENTS; LIMITATIONS.— ‘‘(i) QUORUM.—A quorum shall consist of a total of 13 members of the Board, excluding ex-officio mem- bers, with diverse representation as described in clause (iii). ‘‘(ii) CHAIRPERSON OR VICE CHAIRPERSON.—Each meeting of the Board shall be attended by either the Chairperson or the Vice Chairperson. ‘‘(iii) DIVERSE REPRESENTATION.—At each meeting of the Board, there shall be not less than one scientist, one representative of a disease advocacy organization, and one representative of a professional venture capital or private equity organization. Recommenda- tions.